TITLE:
Clinical Profile of Carcinoma Breast Patients Treated with Trastuzumab: A Single Centre Study
AUTHORS:
Srinivasa Belagutty Jayappa, Bhanu Prakash Lalkota, Veluswamy Mani, Reshma Elsa Jenny, Kiran P. Krishnamurthi, Vinu Sarathy, S. Thineshwaran, Bayas Nithin, Sumithra Martinovic, Amritanshu Ram, Shekar Patil, Radheshyam Naik
KEYWORDS:
Breast Cancer, Trastuzumab, Biosimilars
JOURNAL NAME:
Advances in Breast Cancer Research,
Vol.9 No.4,
September
15,
2020
ABSTRACT: Introduction: Breast cancer is the most common
female cancer in India and accounting for almost 1 in 4 cancer cases
in women worldwide. According to GLOBOCAN 2018: breast cancer incidence is
increased to 162,468 in 2018 compared to 144,937 in
2012. Biosimilar drugs allow expanding access to the therapies in the form of
cost savings and leading to better overall health outcomes. Our study evaluates
the efficacy and safety of Trastuzumab biosimilars and assesses overall
survival in the study population. Materials & Methods: This prospective study was conducted in Healthcare Global Enterprises
Ltd., Bengaluru, India, and all female patients diagnosed with Her2 positive,
metastatic (mBC) and Locally advanced breast cancer (LABC), between March 2013
and November 2014, with at least 4 years of post-treatment follow up. Results: A total of 65 patients diagnosed with Her2 positive breast cancer and satisfied
the selection criteria were included for the study. Partial Response (PR) was
observed in 42 (64.6%) patients, Stable Disease (SD) in 11 (16.9%) patients and
Progressive Disease (PD) in 12 (18.5%) patients. The overall response rates
were 46.1% PR, 30% SD, 23.8% PD in metastatic population and 76% PR, 7.2% SD,
15% PD observed in locally advanced disease. The mean overall survival of the
study population was 20.75 ± 15.20 months in metastatic and 29.2 ± 17.06 months in locally advanced patients. Conclusion: This
prospective study shows the effectiveness of Trastuzumab for HER2-positive in
locally advanced and metastatic breast cancer. The response rates, survival and
toxicity correlate with other global studies. The response and survival are as same as either generic or original Trastuzumab.